The high incidence of prostate cancer (PCa) and benign prostatic hypertrophy (BPH) in elderly men is a cause of increasing public health concern. In recent years, various environmental endocrine disruptors, such as bisphenol A (BPA), have been shown to disrupt sexual organs, including the prostate gland. However, the mechanisms underlying these effects remain unclear. Because androgens and estrogens are important factors in prostate physiopathology, our objective was to examine in rat ventral prostate the effects of adult exposure to BPA on 5α-Reductase isozymes (5α-R types 1, 2, and 3) and aromatase, key enzymes in the biosynthesis of dihydrotestosterone and estradiol, respectively. Adult rats were subcutaneously injected for four days with BPA (25, 50, 300, or 600 µg/Kg/d) dissolved in vehicle. Quantitative RT-PCR, western blot and immunohistochemical analyses showed lower mRNA and protein levels of 5α-R1 and 5α-R2 in BPA-treated groups versus controls but higher mRNA levels of 5α-R3, recently proposed as a biomarker of malignancy. However, BPA treatment augmented mRNA and protein levels of aromatase, whose increase has been described in prostate diseases. BPA-treated rats also evidenced a higher plasma estradiol/testosterone ratio, which is associated with prostate disease. Our results may offer new insights into the role of BPA in the development of prostate disease and may be of great value for studying the prostate disease risk associated with exposure to BPA in adulthood.
Citation: Castro B, Sánchez P, Torres JM, Preda O, del Moral RG, Ortega E (2013) Bisphenol A Exposure during Adulthood Alters Expression of Aromatase and 5α-Reductase Isozymes in Rat Prostate. PLoS ONE 8(2): e55905. https://doi.org/10.1371/journal.pone.0055905
Editor: Angel Nadal, Universidad Miguel Hernández de Elche, Spain
Received: July 2, 2012; Accepted: January 4, 2013; Published: February 6, 2013
Copyright: © 2013 Castro et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The source of funding that has supported the work is European Fund of Regional Development (FEDER-BFU2008-05340). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript
Competing interests: The authors have declared that no competing interests exist.
Bisphenol A (BPA) is an environmental endocrine disruptor used extensively in the production of polycarbonate plastics and in the epoxy linings of food and beverage cans as well as in dental products , . Exposure to BPA is nearly universal; in a recent study, BPA was detected in urine samples from 92.6% of a population in the USA . The widespread exposure of humans to BPA and its potential clinical consequences have recently attracted considerable attention from scientists, government advisors, and the popular press. Moreover, the tolerable daily intake (TDI) of BPA (50 µg/Kg/d) established by the USA Environmental Protection Agency (EPA) called into question after reports of adverse effects below this dose .
BPA has been shown to exert endocrine-disrupting effects on reproduction, development, metabolism, and cancer in humans and other species , . Recent findings linked exposure to BPA with several male reproductive disorders – and prostate diseases –, although the specific mechanisms of action have yet to be elucidated. Most studies have demonstrated that administration of low-doses of BPA during early life, when tissues are especially sensitive to endocrine disrupting chemicals, significantly affect several aspects of prostate development , . However, little data have been published on the effects of adult exposure to BPA on the prostate gland. Chitra et al.  have shown that administration of BPA to adult rat at low dose increases weight of ventral prostate. Other authors have demonstrated that adult exposure to high-dose of BPA can induce expression of cytokeratin 10 (a protein related with squamous metaplasia) in mouse prostatic epithelium .
Androgens are essential for the development, maturation, and function of the prostate gland and have also been implicated in benign and malignant prostate disorders, such as benign prostatic hypertrophy (BPH) and prostate cancer (PCa) , , which are highly common diseases among males in industrialized countries . The most potent androgen in the prostate is 5α-dihydrotestosterone (DHT), obtained from circulating testosterone (T) by the enzyme 5α-Reductase (5α-R, EC 188.8.131.52), which is expressed as three isozymes, types 1, 2, and 3 , . 5α-R1 and 5α-R2 isozymes play an important role in prostate disease, and a specific 5α-R2 inhibitor, finasteride, and the dual inhibitor of 5α-R1 and 5α-R2, dutasteride, have been largely used in the treatment of BPH and PCa , . Less is known about 5α-R3 isozyme. It has been reported that 5α-R3 may play an important role in protein glycosylation . Mutations of 5α-R3 result in congenital disorders ,  and Kahrizi syndrome . Furthermore, over-expression of 5α-R3 has been reported in different cancer types and it has been proposed as a biomarker of malignancy .
Recently published data suggest a role for estrogen in prostate pathogenesis via multiple mechanisms , including direct genotoxicity, epigenotoxicity, hyperprolactinemia, chronic inflammation and prostatic estrogen receptor-mediated events . It is supported by previous evidence of reduced plasma T levels and elevated plasma estradiol (E2) levels in patients with BPH ,  and of a higher E2/T ratio in aging men at greater risk of prostate disease . However, the variation in serum concentrations of E2 may not accurately reflect intraprostatic levels, because E2 is produced from T by the enzyme aromatase (CYP19A1, EC184.108.40.206), which interestingly is increased in the malignant human prostate . Aromatase expression is known to be modified by BPA in various tissues , , but this effect has not been explored to date in the adult prostate. Given that BPA is capable of binding to estrogen receptors and androgen receptor in prostate  and that T is converted to DHT by 5α-R isozymes, we hypothesized that BPA may also modify 5α-R isozymes.
With this background, the objective of this study was to examine in rat ventral prostate the effects of adult BPA exposure on the expression of aromatase and 5α-R isozymes and explore the possible molecular mechanisms of action of BPA in the development of prostate diseases.
Materials and Methods
Experiments were performed strictly in accordance with recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. Animal care and experimental procedures were approved by the Animal Experimentation Ethics Committee of the University of Granada, Spain (Ref. 412-2012-CEEA).
Adult male Wistar rats weighing 260–280 g were housed in an air-conditioned room with fluorescent lights on from 08:00 to 20:00 and given standard laboratory pellet chow (Panlab rodent chow, Barcelona, Spain). Although the concentration of phytoestrogens in the diet was not evaluated, all animals were exposed to the same phytoestrogen levels because the food intake was equivalent for control and BPA-treated rats. Exposure to environmental endocrine disruptors was minimized by housing the rats in stainless steel cages and using glass bottles with rubber stoppers to supply them with tap water.
We evaluated the effect of BPA at the TDI (50 µg/Kg/d) and at higher and lower doses, given that xenoestrogens can cause opposite effects according to the dosage . For this purpose, rats were subcutaneously injected daily for 4 days with 0.2 mL sesame oil containing BPA (Sigma-Aldrich >99% purity) at doses of 25, 50, 300, or 600 µg/Kg/d or with sesame oil alone (controls). Each study group comprised 8 animals.
At 30 min after the final injection, rats were euthanized by decapitation, and the prostate was removed, frozen in liquid nitrogen, and stored at −80°C until analysis. Blood samples were collected in heparinized tubes. The blood was centrifuged at 2000 rpm for 10 min. The plasma was separated and stored at −20°C until the hormone analysis.
Plasma T concentrations were measured by RIA using a commercial DiaSorin kit (Vercelli, Italy) without modifications; intra- and inter-assay coefficients of variation were 7.6% and 12.0%, respectively, and the sensitivity was 0.05 ng/mL. Plasma E2 concentrations were measured by RIA using a commercial DiaSorin kit (Vercelli, Italy) without modifications; intra- and inter-assay coefficients of variation were 4.8% and 9.5%, respectively, and the sensitivity was 12 pg/mL.
RNA extraction and reverse transcription
Total RNA was extracted from 50 mg of rat ventral prostate tissue with Trizol reagent (Invitrogen) according to the instructions of the Sanger Institute©. RNA samples were then treated with Turbo-DNAse (Ambion) to remove any contamination with genomic DNA. The quantity and purity was determined by using a NanoDrop ND-1000 spectrophotometer (A260/280 ratio), and the integrity was tested by means of denaturing gel electrophoresis. First-strand cDNA was synthesized from 1 µg of total RNA by using MuLV reverse transcriptase (Applied Biosystem). The following agents were added to a final volume of 20 µL reaction: 5 mM MgCl2, 1×RT buffer, 1 mM each dNTP, 1 U/µL RNase inhibitor, 2.5 U/µL MuLV reverse transcriptase, 2.5 µM Oligo (dT)16, and 1 µg total RNA. Reactions were incubated at 42°C for 15 min, followed by 5 min at 99°C.
Quantitative Real-Time PCR
Absolute quantification of mRNA of 5α-R1, 5α-R2, 5α-R3, and aromatase in rat prostate tissues was performed by real-time PCR using the Techne Quantica™ Real-time PCR system with SYBR Green PCR Master Mix (Promega). In comparison to relative quantification, this method offers the advantage of giving an absolute copy number for a specific target. The amount of mRNA was expressed as number of mRNA copies per micrograms of total RNA. We amplified tissue samples during real-time PCR in parallel with standard curves, following the method described by Fronhoffs et al. .
The PCR profile was as follows: denaturation at 94°C for 30 seconds; annealing at 55°C for the Srd5a1 gene, 55°C for the Srd5a2 gene, 50°C for the Srd5a3 gene, 60°C for the Cyp19a1 gene for 30 seconds; and extension at 72°C for 30 seconds. The number of cycles was 40 in all cases. At the end of the amplification phase, a melting curve analysis was carried out on the products formed in order to confirm that a single PCR product was detected by the SYBR Green dye.
Primers for 5α-R1 (Srd5a1 mRNA, Genbank accession n° NM_017070.3), 5α-R2 (Srd5a2 mRNA, Genbank accession n° NM_022711.4), 5α-R3 (Srd5a3 mRNA Genbank accession n° NM_001013990.1) and aromatase (Cyp19a1 mRNA Genbank accession n° NM_017085.2) were designed using Primer 3 software. The primer sequences (5′- 3′) are given in Table 1.
Expressions of 5α-R1, 5α-R2, and aromatase were determined by immunohistochemistry on formalin-fixed, paraffin-embedded sections of both rat prostate lobules. Tissue sections were treated for 20 min at 98°C in EDTA buffer (1 mM, pH 8) in a PT module (Thermo Fisher, Fremont, CA) for simultaneous dewaxing, hydrating, and antigenic unmasking (retrieval). Immunohistochemical staining was done automatically (Autostainer 480, Thermo Fisher, Fremont, CA) with commercial antibodies against 5α-R1 (goat polyclonal, sc-20658) and 5α-R2 (rabbit polyclonal, sc-20659) (Santa Cruz Biotechnology Inc, Santa Cruz Ca, USA) at 1∶25 dilution and against aromatase (mouse monoclonal clone H4, MCA2077S) (AbD Serotec, Oxford, UK) at 1∶50 dilution. Immunoenzyme peroxidase polymer (anti-goat and Universal; anti-mouse & anti-rabbit) and diaminobenzidine chromogen (Master Diagnóstica, Granada, Spain) were used as detection systems. A dark-brown cytoplasmic and/or nuclear staining was considered positive. Non-specific polyclonal immunoglobulin or IgG isotype was used as negative control for the corresponding antibody. Immunohistochemical expressions of 5α-R1, 5α-R2 and aromatase were semiquantitatively evaluated using a 4-point scale (0, absence; 1, mild; 2, moderate; 3, high) for glandular and/or stromal cell expression.
Electrophoresis and Western blot analysis
Cytoplasmic and nuclear proteins were extracted from 40 mg of rat ventral prostate tissue with NE-PER extraction reagent (Thermo Scientific), adding protease inhibitor cocktail (Thermo Scientific) according to the manufacturer's protocol. Protein concentration was determined by the dye-binding method of Bradford  with BSA as the standard using Bio-Rad protein assay reagent (Bio-Rad Laboratories, Inc, Richmond, CA, USA). Aliquots of samples containing 50 µg of proteins were subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the proteins were transferred from the gel to PVDF blotting membranes in a buffer containing 25 mM Tris, 190 mM glycine, and 20% methanol. Immunoblotting of the membranes was performed after blocking nonspecific binding with 5% nonfat milk and 0.1% Tween 20 in phosphate-buffered saline (T–PBS) pH 7.5 for 2 h. The blots were incubated overnight at 4°C with primary antibodies at a dilution of 1∶500 for 5α-R1, 1∶200 for 5α-R2, 1∶200 for aromatase, 1∶1000 for β-actin, in T-PBS containing 0.5% non-fat dry milk. After several washing with T-PBS, the blots were incubated for 1 h with the appropriate anti Ig G-horseradish peroxidase (HRP) conjugated secondary antibody at a dilution of 1∶5000. After further washings, the blots were visualized using enhanced chemiluminescence detection system according to the supplier's instructions (ECL-Plus, GE Healthcare, USA). The ImageJ program (http://rsb.info.nih.gov/ij/) was used for quantitative analysis of the bands. To account for any differences in loading, target band densitometries were divided by actin densitometries obtained from the same lane. These corrected densitometries were normalized to controls in each experiment.
Antibodies: Goat anti-5α-R1 (Abcam ab110123), rabbit anti-5α-R2 (Santa Cruz sc-20659), mouse anti-aromatase (ABD serotec MCA2077S). A mouse anti β-actin antibody (Thermo Scientific BA3R) was used as loading control. Goat anti-mouse, goat anti-rabbit and donkey anti-goat Ig G HRP conjugated (Santa Cruz) were used as secondary antibodies.
Data were analyzed by one-way ANOVA. Pairwise comparisons were performed when results proved significant, applying the Tukey method to control for error due to multiple comparisons. P<0.05 was considered significant. All statistical analyses were performed using the STATA Version 10 (Stata Corp. 2007) statistical software.
Plasma Testosterone (T), Estradiol (E2), and E2/T ratio
In comparison to values in the controls, plasma T levels were significantly decreased (Fig. 1A) and E2 levels significantly increased in all BPA-treated groups (Fig. 1B), yielding a higher plasma E2/T ratio (Fig. 1C).
5α-R1, 5α-R2, 5α-R3 and aromatase mRNA levels
In comparison to the controls, 5α-R1 mRNA levels were significantly decreased in all BPA-treated groups (Fig. 2A), with no significant differences among them. 5α-R2 mRNA levels were significantly decreased in all BPA-treated groups versus controls, and the lowest level (around 12-fold vs. controls) was found in the group receiving BPA at doses of 300 and 600 µg/Kg/d (Fig. 2B). In comparison to the controls, 5α-R3 mRNA levels were significantly increased in all BPA-treated groups, with no significant differences among them (Fig. 2C). Likewise, aromatase mRNA levels were significantly increased in all BPA-treated groups versus controls, with no significant differences among them (Fig. 2D).
5α-R1, 5α-R2, and aromatase expression
Microscopic examination of the ventral prostate immunostained slides showed 5α-R1 expression in epithelial cells, mainly in the nucleus (Fig. 3), and 5α-R2 expression in the cytoplasm of both epithelial and stromal cells, with additional nuclear staining in the BPA-treated rats (Fig. 3 and Fig. S1). Expression of both 5α-R1 and 5α-R2 was lower in the BPA-treated groups than in the control group. Unfortunately, there are no commercially available antibodies at present for 5α-R3. Aromatase was expressed mostly in the cytoplasm of the epithelial cells; aromatase expression was higher in BPA-treated rats than in the control group, except at the 25 µg/Kg/d dose (Fig. 4 and Fig. S2).
Figure 5 (panel A) depicts the expression of 5α-R1 isozyme in ventral prostate of control male rats (lane 1) and male rats treated with BPA at the 50 µg/Kg/d dose (TDI) (lane 2). Lower 5α-R1 expression was observed after BPA treatment with respect to control rats.
Equal loading of protein was determined using an anti β-actin antibody. A representative image of three independent experiments is shown for each blot. Normalization for loading differences was achieved by dividing the densitometry values for individual bands by the densitometry values for β-actin in the same lane. Data represent the mean of three independent experiments. #P<0.05 vs. Control animals.
Figure 5 (panel B) depicts the expression of 5α-R2 isozyme in ventral prostate of control male rats (lane 1) and male rats treated with BPA at the 50 µg/Kg/d dose (TDI) (lane 2). Lower 5α-R2 expression was observed after BPA treatment with respect to control rats.
Figure 5 (panel C) depicts the expression of aromatase in ventral prostate of control male rats (lane 1) and male rats treated with BPA at the 50 µg/Kg/d dose (TDI) (lane 2). Higher aromatase expression was observed after BPA treatment with respect to control rats.
Equal loading of protein in tissue homogenates was also determined by Western blot using an anti-β-actin antibody. All blots were repeated three times and one representative image is shown.
This study contributes the first evidence that adult exposure to BPA influences the expression of 5α-R isozymes and aromatase in the rat prostate. Our experimental results demonstrate that the short-term administration of BPA to adult rats is associated with a decrease in mRNA and protein levels of both 5α-R1 and 5α-R2 isozymes. Within the prostate 5α-R1 and 5α-R2 are positively regulated by T , , consistent with the present results. BPA may down regulate these isozymes by reducing circulating T levels through decreasing luteinizing hormone (LH) secretion; or interfering with the LH receptor , or inhibiting T biosynthetic enzymes . BPA may also exert these effects through the androgen receptor, although reports have been controversial .
The localization of 5α-R2 in this study was mainly in the cytoplasm, in agreement with Span et al. , although an additional nuclear staining was observed in BPA-treated rats. Interestingly, Thomas et al.  observed that 5α-R2 was predominantly cytoplasmic in recurrent cancer but some nuclear staining was also present. However, the functional significance of the nuclear localization of 5α-R2 remains still unclear.
Our BPA-treated rats showed increased mRNA levels of 5α-R3 (a suggested malignancy biomarker) in association with decreased plasma T levels. Li et al.  found a transition from positive to negative regulation of 5α-R3 by androgens in the development and progression of PCa. Although our results point to this line, further studies e.g. longer BPA exposure, are required to link the data at molecular levels after BPA exposure with prostate pathologies.
There is adequate evidence to relate androgens to prostate disease, but other factors may also be implicated, given that the prevalence of prostate pathologies increases with age when circulating T levels decline. Estrogens may also play a critical role in predisposing for or causing prostate disease . Numerous epidemiological studies have reported a relationship between elevated circulating estrogen levels or E2/T ratio and prostate disease, including PCa . In the present study, an increase in E2 and decrease in T, i.e., a higher E2/T ratio, were induced by the administration of BPA.
If elevated intraprostatic E2 levels are involved in PCa , aromatase may play an important role in the development of this disease. The present results demonstrate that BPA administration increases aromatase mRNA and protein levels in the prostate of adult rats. However, there was a lower increase in protein than in mRNA levels of this enzyme at a dose of 25 µg/Kg/d. There may possibly be some post-transcriptional defense mechanism to avoid aromatase gene overexpression at low doses of BPA.
To our knowledge, this is the first report on the effects of BPA on aromatase in adult rat prostate. Arase et al.  demonstrated that fetal exposure to low-dose BPA increases in situ E2 and aromatase mRNA and enzymatic activity in the mouse urogenital sinus from which the prostate develops. However, in vitro studies in other cellular types found decreased aromatase levels after BPA administration , . Differences between the adult and the developing prostate, animal, tissue, endocrine system, and in vitro versus in vivo studies should be kept in mind.
The present study contributes the first evidence that adult exposure to BPA modifies in the rat prostate gland the expression of 5α-R isozymes and aromatase, key enzymes in the prostatic physiopathology. These effects were observed over the short-term and at levels at or below the TDI for this compound. Our study opens up a new line of investigation on the risk of prostate disease associated with exposure to BPA in adulthood.
Immunohistochemical staining of 5α-Reductase type 1 (5α-R1) and 5α-Reductase type 2 (5α-R2) in prostate of control and BPA-treated rats at doses of 25, 50, 300, or 600 µg/Kg/d for 4 days. Magnification ×200.
The authors thank R. Davies for revising the English text. The authors are indebted to M. Quintana and R. Arcas for their technical assistance.
Conceived and designed the experiments: EO. Performed the experiments: BC PS JMT OP. Analyzed the data: BC PS JMT OP RGM EO. Contributed reagents/materials/analysis tools: EO RGM OP. Wrote the paper: BC PS JMT EO.
- 1. Goodson A, Robin H, Summerfield W, Cooper I (2004) Migration of bisphenol A from can coatings–effects of damage, storage conditions and heating. Food Addit Contam 10: 1015–1026.
- 2. Olea N, Pulgar R, Pérez P, Olea-Serrano F, Rivas A, et al. (1996) Estrogenicity of resin-based composites and sealants used in dentistry. Environ Health Perspect 104: 298–305.
- 3. Rubin BS, Soto AM (2009) Bisphenol A: Perinatal exposure and body weight. Mol Cell Endocrinol 25: 55–62.
- 4. Vom Saal FS, Hughes C (2005) An Extensive New Literature Concerning Low-Dose Effects of Bisphenol A. Shows the Need for a New Risk Assessment. Environ Health Perspect 113: 926–933.
- 5. Rubin BS (2011) Bisphenol A: An endocrine disruptor with widespread exposure and multiple effects. J Steroid Biochem Mol Biol 127: 27–34.
- 6. Soto AM, Sonnenschein C (2010) Environmental causes of cancer: endocrine disruptors as carcinogens. Nat Rev Endocrinol 6: 363–370.
- 7. Richter CA, Birnbaum LS, Farabollini F, Newbold RR, Rubin BS, et al. (2007) In vivo effects of bisphenol A in laboratory rodent studies. Reprod Toxicol 24: 199–224.
- 8. Walker DM, Gore AC (2011) Transgenerational neuroendocrine disruption of reproduction. Nat Rev Endocrinol 7: 197–207.
- 9. Takao T, Nanamiya W, Nagano I, Asaba K, Kawabata K, et al. (1999) Exposure with the environmental estrogen bisphenol A disrupts the male reproductive tract in young mice. Life Sci 65: 2351–2357.
- 10. Chitra KC, Latchoumycandane C, Mathur PP (2003) Induction of oxidative stress by bisphenol A in the epididymal sperm of rats. Toxicology 14: 119–127.
- 11. De Flora S, Micale RT, La Maestra S, Izzotti A, D'Agostini F, et al. (2011) Upregulation of clusterin in prostate and DNA damage in spermatozoa from bisphenol A-treated rats and formation of DNA adducts in cultured human prostatic cells. Toxicol Sci 122: 45–51.
- 12. Ho SM, Tang WY, Belmonte de Frausto J, Prins GS (2006) Developmental exposure to estradiol and bisphenol A increases susceptibility to prostate carcinogenesis and epigenetically regulates phosphodiesterase type 4 variant. Cancer Res 1: 5624–5632.
- 13. Taylor JA, Richter CA, Ruhlen RL, vom Saal FS (2011) Estrogenic environmental chemicals and drugs: mechanisms for effects on the developing male urogenital system. J Steroid Biochem Mol Biol 127: 83–95.
- 14. Welshons WV, Nagel SC, vom Saal FS (2006) Large effects from small exposures. III. Endocrine mechanisms mediating effects of bisphenol A at levels of human exposure. Endocrinology 147: 56–69.
- 15. Vandenberg LN, Colborn T, Hayes TB, Heindel JJ, Jacobs DR Jr, et al. (2012) Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev 33: 378–455.
- 16. Ogura Y, Ishii K, Kanda H, Kanai M, Arima K, et al. (2007) Bisphenol A induces permanent squamous change in mouse prostatic epithelium. Differentiation 75: 745–756.
- 17. Imamoto T, Suzuki H, Utsumi T, Endo T, Takano M, et al. (2009) Association between serum sex hormone levels and prostate cancer: effect of prostate cancer on serum testosterone levels. Future Oncol 5: 1005–1013.
- 18. Nicholson TM, Ricke WA (2011) Androgens and estrogens in benign prostatic hyperplasia: past, present and future. Differentiation 82: 184–199.
- 19. Cooperberg MR, Moul JW, Carroll PR (2005) The changing face of prostate cancer. J Clin Oncol 10: 8146–8151.
- 20. Russell DW, Wilson JD (1994) Steroid 5 alpha-reductase: two genes/two enzymes. Annu Rev Biochem 63: 25–61.
- 21. Uemura M, Tamura K, Chung S, Honma S, Okuyama A, et al. (2008) Novel 5 alpha-steroid reductase (SRD5A3, type-3) is overexpressed in hormone-refractory prostate cancer. Cancer Sci 99: 81–86.
- 22. Kaplan SA (2012) Comparison of Dutasteride and Finasteride for Treating Benign Prostatic Hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). J Urol 187: 584–585.
- 23. Rittmaster R, Hahn RG, Ray P, Shannon JB, Wurzel R (2008) Effect of dutasteride on intraprostatic androgen levels in men with benign prostatic hyperplasia or prostate cancer. Urology 72: 808–812.
- 24. Cantagrel V, Lefeber DJ, Ng BG, Guan Z, Silhavy JL, et al. (2010) SRD5A3 is required for converting polyprenol to dolichol and is mutated in a congenital glycosylation disorder. Cell 142: 203–217.
- 25. Morava E, Wevers RA, Cantagrel V, Hoefsloot LH, Al-Gazali L, et al. (2010) A novel cerebello-ocular syndrome with abnormal glycosylation due to abnormalities in dolichol metabolism. Brain 133: 3210–3220.
- 26. Kahrizi K, Hu CH, Garshasbi M, Abedini SS, Ghadami S, et al. (2011) Next generation sequencing in a family with autosomal recessive Kahrizi syndrome (OMIM 612713) reveals a homozygous frameshift mutation in SRD5A3. Eur J Hum Genet 19: 115–117.
- 27. Godoy A, Kawinski E, Li Y, Oka D, Alexiev B, et al. (2011) 5α-reductase type 3 expression in human benign and malignant tissues: a comparative analysis during prostate cancer progression. Prostate 71: 1033–1046.
- 28. Ho CK, Habib FK (2011) Estrogen and androgen signaling in the pathogenesis of BPH. Nat Rev Urol 8: 29–41.
- 29. Nelles JL, Hu WY, Prins GS (2011) Estrogen action and prostate cancer. Expert Rev Endocrinol Metab 6: 437–451.
- 30. Ortega E, Ruiz E, Mendoza MC, Martin-Andres A, Osorio C (1979) Plasma steroid and protein hormone concentrations in patients with benign prostatic hypertrophy and in normal men. Experientia 35: 844–845.
- 31. Tan MO, Karabiyik I, Uygur MC, Diker Y, Erol D (2003) Serum concentrations of sex hormones in men with severe lower urinary tract symptoms and benign prostatic hyperplasia. Int Urol Nephrol 35: 357–363.
- 32. Ellem SJ, Schmitt JF, Pedersen JS, Frydenberg M, Risbridger GP (2004) Local aromatase expression in human prostate is altered in malignancy. J Clin Endocrinol Metab 89: 2434–2441.
- 33. Arase S, Ishii K, Igarashi K, Aisaki K, Yoshio Y, et al. (2011) Endocrine disrupter bisphenol A increases in situ estrogen production in the mouse urogenital sinus. Biol Reprod 84: 734–742.
- 34. Xi W, Lee CK, Yeung WS, Giesy JP, Wong MH, et al. (2011) Effect of perinatal and postnatal bisphenol A exposure to the regulatory circuits at the hypothalamus-pituitary-gonadal axis of CD-1 mice. Reprod Toxicol 31: 409–417.
- 35. Vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, et al. (1997) Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc Natl Acad Sci USA 94: 2056–2061.
- 36. Fronhoffs S, Totzke G, Stier S, Wernert N, Rothe M, et al. (2002) A method for the rapid construction of cRNA standard curves in quantitative real-time reverse transcription polymerase chain reaction. Mol Cell Probes 16: 99–110.
- 37. Bradford MN (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye-binding. Anal Biochem 72: 248–254.
- 38. Li J, Ding Z, Wang Z, Lu JF, Maity SN, et al. (2011) Androgen regulation of 5α-reductase isoenzymes in prostate cancer: implications for prostate cancer prevention. PLoS One 6: e28840.
- 39. Torres JM, Ruiz E, Ortega E (2003) Development of a quantitative RT-PCR method to study 5alpha-reductase mRNA isozymes in rat prostate in different androgen status. Prostate 15: 74–79.
- 40. Akingbemi BT, Sottas CM, Koulova AI, Klinefelter GR, Hardy MP (2004) Inhibition of testicular steroidogenesis by the xenoestrogen bisphenol A is associated with reduced pituitary luteinizing hormone secretion and decreased steroidogenic enzyme gene expression in rat Leydig cells. Endocrinology 145: 592–603.
- 41. Ye L, Zhao B, Hu G, Chu Y, Ge RS (2011) Inhibition of human and rat testicular steroidogenic enzyme activities by bisphenol A. Toxicol Lett 207: 137–142.
- 42. Wetherill YB, Akingbemi BT, Kanno J, McLachlan JA, Nadal A, et al. (2007) In vitro molecular mechanisms of bisphenol A action. Reprod Toxicol 24: 178–198.
- 43. Span PN, Sweep CG, Benraad TJ, Smals A (1996) Differential subcellular distribution of rat prostatic steroid 5alpha-reductase isozyme activities. Eur J Endocrinol 134: 386–392.
- 44. Thomas LN, Lazier CB, Gupta R, Norman RW, Troyer DA, et al. (2005) Differential alterations in 5alpha-reductase type 1 and type 2 levels during development and progression of prostate cancer. Prostate 63: 231–239.
- 45. Santti R, Newbold RR, Makela S, Pylkkanen L, McLachlan JA (1994) Development of estrogenization and prostatic neoplasia. Prostate 24: 67–78.
- 46. Ricke WA, McPherson SJ, Bianco JJ, Cunha GR, Wang Y, et al. (2008) Prostatic hormonal carcinogenesis is mediated by in situ estrogen production and estrogen receptor alpha signaling. FASEB J 22: 1512–1520.
- 47. Kwintkiewicz J, Nishi Y, Yanase T, Giudice LC (2010) Peroxisome proliferator-activated receptor-gamma mediates bisphenol A inhibition of FSH-stimulated IGF-1, aromatase, and estradiol in human granulosa cells. Environ Health Perspect 118: 400–406.
- 48. Kamat A, Hinshelwood MM, Murry BA, Mendelson CR (2002) Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol Metab 13: 122–128.